Skip to content
HowShorted

ATOSSA THERAPEUTICS, INC. short interest in 2024

In 2024, ATOSSA THERAPEUTICS, INC.'s disclosed short interest ran from 5.57% of shares outstanding on 12 Jan 2024 to 6.81% on 31 Dec 2024, a change of +1.24 percentage points. The year's high was 10.48% on 13 Sep 2024 and its low 5.46% on 31 Jan 2024, averaging 8.57% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 33.12 days on 31 Oct 2024. Full history: ATOSSA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ATOSSA THERAPEUTICS, INC. in 2024

2024 in figures

Start of year
5.57% (12 Jan 2024)
End of year
6.81% (31 Dec 2024)
Change
+1.24 pp
High
10.48% (13 Sep 2024)
Low
5.46% (31 Jan 2024)
Average
8.57%
Highest days to cover
33.12 (31 Oct 2024)
SEC filings marked
8

Every report in 2024

ATOSSA THERAPEUTICS, INC. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20245.57%16.53
31 Jan 20245.46%21.52
15 Feb 20245.61%15.16
29 Feb 20245.71%16.62
15 Mar 20246.77%6.68
28 Mar 20248.43%3.42
15 Apr 20249.86%3.6310-K filed, results (8-K)
30 Apr 20249.13%7.02
15 May 20249.13%8.0310-Q filed, results (8-K)
31 May 20248.92%11.14
14 Jun 20248.66%15.55
28 Jun 20248.18%3.57
15 Jul 20249.81%12.76
31 Jul 202410.11%15.06
15 Aug 202410.23%21.9310-Q filed, results (8-K)
30 Aug 202410.26%23.71
13 Sep 202410.48%26.12
30 Sep 202410.28%20.94
15 Oct 202410.38%31.12
31 Oct 202410.15%33.12
15 Nov 20249.90%14.4710-Q filed, results (8-K)
29 Nov 20249.22%14.85
13 Dec 20246.52%8.98
31 Dec 20246.81%8.13

See also: ATOSSA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.